Clinical Data Boehringer/Zealand dual-acting drug causes 16.6% weight loss PharmaphorumBoehringer/Zealand reveal first phase 3 data with dual GLP-1/glucagon weight-loss drug survodutide.Metabolic & GLP-1Read full story pharminent April 28, 2026 (Last updated: April 28, 2026) Pharmaphorum Boehringer/Zealand reveal first phase 3 data with dual GLP-1/glucagon weight-loss drug survodutide. Metabolic & GLP-1 Read full story Please leave this field emptySign up to receive free daily digest Check your inbox or spam folder to confirm your subscription. Post navigation Previous: BioMarin acquires Amicus Therapeutics for $4.8bnNext: Seaport and Hemab target $180m IPOs as biotech listings accumulate Related Stories Clinical Data Parsortix study shows promise for ADC target detection pharminent August 3, 2026 Clinical Data Novo setback casts doubt on a new way to treat heart disease pharminent July 31, 2026 Clinical Data Altimmune rises as GLP-1/GIP drug curbs heavy drinking in mid-stage study pharminent July 28, 2026
